Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.

Genetic Predisposition to an Impaired Metabolism of the Branched-Chain Amino Acids and Risk of Type 2 Diabetes: A Mendelian Randomisation Analysis

Open access

Abstract

BACKGROUND: Higher circulating levels of the branched-chain amino acids (BCAAs; i.e., isoleucine, leucine, and valine) are strongly associated with higher type 2 diabetes risk, but it is not known whether this association is causal. We undertook large-scale human genetic analyses to address this question. METHODS AND FINDINGS: Genome-wide studies of BCAA levels in 16,596 individuals revealed five genomic regions associated at genome-wide levels of significance (p < 5 × 10-8). The strongest signal was 21 kb upstream of the PPM1K gene (beta in standard deviations [SDs] of leucine per allele = 0.08, p = 3.9 × 10-25), encoding an activator of the mitochondrial branched-chain alpha-ketoacid dehydrogenase (BCKD) responsible for the rate-limiting step in BCAA catabolism. In another analysis, in up to 47,877 cases of type 2 diabetes and 267,694 controls, a genetically predicted difference of 1 SD in amino acid level was associated with an odds ratio for type 2 diabetes of 1.44 (95% CI 1.26-1.65, p = 9.5 × 10-8) for isoleucine, 1.85 (95% CI 1.41-2.42, p = 7.3 × 10-6) for leucine, and 1.54 (95% CI 1.28-1.84, p = 4.2 × 10-6) for valine. Estimates were highly consistent with those from prospective observational studies of the association between BCAA levels and incident type 2 diabetes in a meta-analysis of 1,992 cases and 4,319 non-cases. Metabolome-wide association analyses of BCAA-raising alleles revealed high specificity to the BCAA pathway and an accumulation of metabolites upstream of branched-chain alpha-ketoacid oxidation, consistent with reduced BCKD activity. Limitations of this study are that, while the association of genetic variants appeared highly specific, the possibility of pleiotropic associations cannot be entirely excluded. Similar to other complex phenotypes, genetic scores used in the study captured a limited proportion of the heritability in BCAA levels. Therefore, it is possible that only some of the mechanisms that increase BCAA levels or affect BCAA metabolism are implicated in type 2 diabetes. CONCLUSIONS: Evidence from this large-scale human genetic and metabolomic study is consistent with a causal role of BCAA metabolism in the aetiology of type 2 diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pmed.1002179

Cites

73 of 73 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Design of the study. DIAGRAM, DIAbetes Genetics Replication And Meta-analysis.
Fig 1 Design of the study. DIAGRAM, DIAbetes Genetics Replication And Meta-analysis.CC BY · PubMed Central
Fig 2 Manhattan plot of the association of genetic variants with the levels of branched-chain amino acids.
Fig 2 Manhattan plot of the association of genetic variants with the levels of branched-chain amino acids.CC BY · PubMed Central
Fig 3 Genetically predicted or measured levels of the branched-chain amino acids and risk of type 2 diabetes. (A) Comparison of (i) the association of a difference of 1 SD in the levels of BCAAs at baseline with incident type 2 diabetes in prospective observational studies (bars with blue circles) and (ii) the association of a genetically predicted difference of 1 SD in BCAA levels with type 2 diabetes in genetic Mendelian randomisation studies (bars with red squares for analyses of independent genetic variants and bars with orange diamonds for analyses of correlated genetic variants). (B) Regional association plots for the association of variants at the PPM1K locus with valine (top; representative of the three BCAAs) and type 2 diabetes (bottom). Associations were characterised by a peak of signal upstream of the PPM1K gene, with the lead rs1440581 polymorphism and other polymorphisms in high linkage disequilibrium, as well as a peripheral signal overlaying the gene, with variants in lower linkage disequilibrium with the lead polymorphism. (C) Scatter plot of the association of the isoleucine-raising alleles included in the isoleucine genetic score with amino acid levels and with type 2 diabetes risk. (D) The association of the quartiles of isoleucine level at baseline with incident type 2 diabetes in the EPIC-Norfolk case-cohort study, the Framingham Offspring Study, and the Malmö Diet and Cancer Study (1,025 cases of incident type 2 diabetes and 1,182 controls). Error bars represent the 95% confidence intervals around the central estimates. BCAA, branched-chain amino acid; OR, odds ratio; RR, relative risk; SD, standard deviation; T2D, type 2 diabetes.
Fig 3 Genetically predicted or measured levels of the branched-chain amino acids and risk of type 2 diabetes. (A) Comparison of (i) the association of a difference of 1 SD in the levels of BCAAs at baseline with incident type 2 diabetes in prospective observational studies (bars with blue circles) and (ii) the association of a genetically predicted difference of 1 SD in BCAA levels with type 2 diabetes in genetic Mendelian randomisation studies (bars with red squares for analyses of independent genetic variants and bars with orange diamonds for analyses of correlated genetic variants). (B) Regional association plots for the association of variants at the PPM1K locus with valine (top; representative of the three BCAAs) and type 2 diabetes (bottom). Associations were characterised by a peak of signal upstream of the PPM1K gene, with the lead rs1440581 polymorphism and other polymorphisms in high linkage disequilibrium, as well as a peripheral signal overlaying the gene, with variants in lower linkage disequilibrium with the lead polymorphism. (C) Scatter plot of the association of the isoleucine-raising alleles included in the isoleucine genetic score with amino acid levels and with type 2 diabetes risk. (D) The association of the quartiles of isoleucine level at baseline with incident type 2 diabetes in the EPIC-Norfolk case-cohort study, the Framingham Offspring Study, and the Malmö Diet and Cancer Study (1,025 cases of incident type 2 diabetes and 1,182 controls). Error bars represent the 95% confidence intervals around the central estimates. BCAA, branched-chain amino acid; OR, odds ratio; RR, relative risk; SD, standard deviation; T2D, type 2 diabetes.CC BY · PubMed Central
Fig 4 Association of branched-chain amino acid genetic scores with metabolites in the Fenland study. Associations of the BCAA scores with the BCAAs are highlighted in dark red. Error bars represent the 95% confidence interval around the central estimate.BCAA, branched-chain amino acid; SD, standard deviation.
Fig 4 Association of branched-chain amino acid genetic scores with metabolites in the Fenland study. Associations of the BCAA scores with the BCAAs are highlighted in dark red. Error bars represent the 95% confidence interval around the central estimate.BCAA, branched-chain amino acid; SD, standard deviation.CC BY · PubMed Central
Fig 5 Schematic representation of the branched-chain amino acid pathway and associations with type 2 diabetes. BCKD, branched-chain alpha-ketoacid dehydrogenase.
Fig 5 Schematic representation of the branched-chain amino acid pathway and associations with type 2 diabetes. BCKD, branched-chain alpha-ketoacid dehydrogenase.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 73 references

Cited by

See all 423

Metadata

Authors
Lotta, L. A., Scott, R. A., Sharp, S. J., Burgess, S., Luan, J., Tillin, T., Schmidt, A. F., Imamura, F., Stewart, I. D., Perry, J. R. B., Marney, L., Koulman, A., Karoly, E. D., Forouhi, N. G., Sjögren, R. J. O., Näslund, E., Zierath, J. R., Krook, A., Savage, D. B., Griffin, J. L., Chaturvedi, N., Hingorani, A. D., Khaw, K.-T., Barroso, I., McCarthy, M. I., O’Rahilly, S., Wareham, N. J., & Langenberg, C.
Affiliations
  • University of Cambridge (GB)
  • University College London (GB)
  • MRC Elsie Widdowson Laboratory (GB)
  • Metabolon (United States) (US)
  • Karolinska Institutet (SE)
  • Danderyds sjukhus (SE)
  • Centre for Human Genetics (GB)
Corresponding author
  • Wareham, Nicholas J.
  • Langenberg, Claudia
Venue
PLOS Medicine
Published
2016-11-29
Volume
13
Issue
11
Pages
e1002179
ISSN
  • 1549-1277 (ISSN-L)
  • 1549-1676
OpenAlex
W2559236589
Cited by
417
References
73
Citations by year
2026: 20 · 2025: 38 · 2024: 43 · 2023: 50 · 2022: 49 · 2021: 61 · 2020: 50 · 2019: 31 · 2018: 52 · 2017: 21 · 2016: 1
FWCI
4.68
Type
journal article
Language
en
Open access
Locations
  • PLoS Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • UCL Discovery (University College London) (submittedVersion)
  • Figshare (submittedVersion, cc-by)
  • Spiral (Imperial College London) (submittedVersion, other-oa)
  • Apollo (University of Cambridge) (submittedVersion, cc-by)
  • Apollo (cc-by)
Funders
  • Medical Research Council (MC_UU_12015/1, MC_PC_13046, MC_PC_13048 and MR/L00002/1 - MRC Epidemiology Unit, MC_UP_A090_1006 - MRC Human Nutrition Research, SABRE Study)
  • National Institute for Health Research (Biomedical Research Centre—MRC Epidemiology Unit)
  • EMIF (n° 115372)
  • Cambridge Lipidomics Biomarker Research Initiative (G0800783 - MRC Epidemiology Unit and MRC Human Nutrition Research)
  • Diabetes UK (SABRE Study)
  • British Heart Foundation (GB) (SABRE Study)
  • Wellcome Trust (GB) (WT082464 - SABRE Study, SP/07/001/23603 - SABRE Study)
  • Diabetes UK (GB) (13/0004774 - SABRE Study)
  • Vetenskapsrådet (Rasmus J O Sjögren, Erik Näslund, Juleen R. Zierath and Anna Krook)
  • Novo Nordisk Foundation (Rasmus J O Sjögren, Erik Näslund, Juleen R. Zierath and Anna Krook)
  • Diabetes Wellness (Rasmus J O Sjögren, Erik Näslund, Juleen R. Zierath and Anna Krook)
  • Wellcome Trust (107064, 090532, 098381, WT098051)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Nutrition, Genetics, and Disease
Keywords
branched-chain amino acids, type 2 diabetes, branched-chain amino acid metabolism, PPM1K, branched-chain ketoacid dehydrogenase, genetic susceptibility, causal inference, isoleucine, leucine, valine, circulating amino acids, polygenic risk score, heritability, pleiotropy, mitochondrial metabolism, metabolite accumulation
MeSH terms
Adult, Aged, Amino Acids, Branched-Chain, Diabetes Mellitus, Type 2, Humans, Male, Middle Aged, Prospective Studies, Risk Factors, Sweden, Genetic Predisposition to Disease, Genome-Wide Association Study, Young Adult, Mendelian Randomization Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genetic Predisposition to an Impaired Metabolism of the Branched-Chain Amino Acids and Risk of Type 2 Diabetes: A Mendelian Randomisation Analysis. https://app.cochat.ai/papers/10.1371/journal.pmed.1002179
The paper
Lotta, L. A., Scott, R. A., Sharp, S. J., Burgess, S., Luan, J., Tillin, T., Schmidt, A. F., Imamura, F., Stewart, I. D., Perry, J. R. B., Marney, L., Koulman, A., Karoly, E. D., Forouhi, N. G., Sjögren, R. J. O., Näslund, E., Zierath, J. R., Krook, A., Savage, D. B., . . . Langenberg, C. (2016). Genetic Predisposition to an Impaired Metabolism of the Branched-Chain Amino Acids and Risk of Type 2 Diabetes: A Mendelian Randomisation Analysis. PLOS Medicine. https://doi.org/10.1371/journal.pmed.1002179

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.